12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Caprelsa vandetanib regulatory update

Germany's Federal Joint Committee (G-BA) issued a final benefit assessment for cancer drug Caprelsa vandetanib from AstraZeneca that was in line with a preliminary assessment from the Institute for Quality and Efficiency in Health Care (IQWiG). G-BA said Caprelsa offers no additional benefit over best supportive...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >